Nathan Emery, MD
Ophthalmology · St Petersburg, FLNPI 1518959048
Payments from drug & device makers
Across 207 payments — averaging $24.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$693
- ANI Pharmaceuticals, Inc.$484
- Rxsight Inc$419
- Amgen$265
- Ocular Therapeutix, Inc.$260
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$4,95399%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 37 | $1,099 |
| AbbVie(2 entities) | 37 | $693 |
| ANI Pharmaceuticals, Inc. | 26 | $484 |
| Rxsight Inc | 7 | $419 |
| Amgen | 8 | $265 |
| Ocular Therapeutix, Inc. | 14 | $260 |
| Mallinckrodt Hospital Products Inc. | 11 | $245 |
| Glaukos Corporation | 10 | $242 |
| Bausch & Lomb Americas Inc. | 9 | $171 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $169 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $143 |
| Sun Pharmaceutical Industries Inc. | 5 | $130 |
| Harrow Eye, LLC | 4 | $94 |
| Tarsus Pharmaceuticals, Inc. | 3 | $92 |
| Oyster Point Pharma, Inc. | 5 | $84 |
| Dompe US, Inc. | 3 | $78 |
| Thea Pharma Inc. | 2 | $50 |
| Eyevance Pharmaceuticals LLC | 2 | $48 |
| Novartis | 2 | $42 |
| Aerie Pharmaceuticals, Inc. | 3 | $42 |
| Biotissue Holdings Inc. | 2 | $42 |
| Lensar, Inc. | 2 | $29 |
| Rayner Intraocular Lenses Limited | 1 | $26 |
| Shire North American Group Inc | 1 | $22 |
| Sight Sciences, Inc. | 1 | $19 |
| NEW World Medical,inc. | 1 | $18 |
| Ivantis, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,024 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 63 | $62,342 |
| MieboPerfluorohexyloctane/Pf | 40 | $31,080 |
| LumiganBimatoprost | 55 | $24,556 |
| VyzultaLatanoprostene Bunod | 51 | $21,604 |
| Prednisolone Acetate | 403 | $21,115 |
| Loteprednol Etabonate | 83 | $20,900 |
| Alphagan PBrimonidine Tartrate | 32 | $14,504 |
| RocklatanNetarsudil Mesylat/Latanoprost | 26 | $12,057 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $10,794 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 23 | $6,436 |
| Latanoprost | 467 | $5,758 |
| Ciprofloxacin Hcl | 359 | $5,714 |
| Cyclosporine | 12 | $5,149 |
| RhopressaNetarsudil Mesylate | 11 | $4,905 |
| Travoprost | 17 | $4,112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $693 | $112,196183 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $171 | $52,68491 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $143 | $20,90083 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $42 | $16,96237 claims |
| AlconSimbrinza | $1,099 | $6,43623 claims |
| Eyevance Pharmaceuticals LLCFlarex | $48 | $2,49913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in St Petersburg
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.